Neoplasms, Colorectal Clinical Trial
Official title:
Green Tea Extracts for the Prevention of Colorectal Adenomas and Colorectal Cancer
Verified date | October 2015 |
Source | Seoul National University Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | Korea: Institutional Review Board |
Study type | Interventional |
Experimental studies have shown the chemopreventive properties of green tea extract (GTE) on colorectal cancer. And colorectal adenomas are precursors to colorectal cancers. The aim of this study is to determine the preventive effect of GTE supplements on metachronous colorectal adenomas by giving GTE tablets of which are equivalent of 9 cup-of-green tea per day (0.9 g/day GTE, 0.6 g/day Epigallocatechin gallate (EGCG).
Status | Completed |
Enrollment | 176 |
Est. completion date | October 2015 |
Est. primary completion date | May 2015 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 19 Years to 85 Years |
Eligibility |
Inclusion Criteria: - subjects who present one or more adenomatous polyps on colonoscopy. Exclusion Criteria: - subjects who denied to participate in this study - subjects who present inflammatory bowel diseases such as ulcerative colitis or crohn's disease - subjects who received partial or total colectomy due to colon cancer or other colonic diseases. - subjects who are pregnant - subjects who are on aspirin or NSAIDS for any reasons - subjects who have received a transplant of any major organ or who are on immunosuppressants for any reason - subjects who are unable to perform a bowel prep or who present poor bowel prep for colonoscopy |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Seoul National University Hospital |
Shimizu M, Fukutomi Y, Ninomiya M, Nagura K, Kato T, Araki H, Suganuma M, Fujiki H, Moriwaki H. Green tea extracts for the prevention of metachronous colorectal adenomas: a pilot study. Cancer Epidemiol Biomarkers Prev. 2008 Nov;17(11):3020-5. doi: 10.115 — View Citation
Stingl JC, Ettrich T, Muche R, Wiedom M, Brockmöller J, Seeringer A, Seufferlein T. Protocol for minimizing the risk of metachronous adenomas of the colorectum with green tea extract (MIRACLE): a randomised controlled trial of green tea extract versus pla — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Recurrence/Number/Size of metachronous colorectal adenoma(s) | 1 year | No | |
Secondary | Recurrence/Number/Size of metachronous colorectal polyp(s) including hyperplastic polyp(s) | 1 year | No | |
Secondary | Change of lipid profiles after green tea extract (GTE) supplementation | 1 year | No | |
Secondary | Change of body weight, BMI and waist circumference | 1 year | No | |
Secondary | Adverse effect(s) of GTE supplementation | every 1-3 months till the end of study protocol (12 months) | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00536809 -
Phase I/II Study of Lapatinib in Combination With Oxaliplatin and Capecitabine in Subjects With Advanced Colorectal Cancer
|
Phase 1 | |
Active, not recruiting |
NCT02395224 -
A Longitudinal Study of Colorectal Cancer Patients With Metastatic Disease in Middle-Norway
|
||
Completed |
NCT00967616 -
Study of CS-7017 in Combination With FOLFIRI in Subjects With Metastatic Colorectal Cancer Who Failed First-Line Therapy
|
Phase 2 | |
Completed |
NCT00704600 -
Nelfinavir, a Phase I/Phase II Rectal Cancer Study
|
Phase 1/Phase 2 | |
Recruiting |
NCT05358249 -
Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
|
Phase 1/Phase 2 | |
Terminated |
NCT01545141 -
Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer
|
Phase 1/Phase 2 | |
Withdrawn |
NCT01157039 -
A Trial of Glutamine to Prevent Oxaliplatin Neurotoxicity and a Pharmacokinetic Analysis of Oxaliplatin
|
Phase 2 | |
Completed |
NCT00387387 -
Study On Pazopanib When Given With FOLFOX6 (Fluorouracil, Oxaliplatin, Leucovorin) Or CapeOx (Capecitabine, Oxaliplatin)
|
Phase 1 | |
Completed |
NCT03428958 -
A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment
|
Phase 1/Phase 2 | |
Recruiting |
NCT04593407 -
Endoscopic Mucosal Resection Versus Endoscopic Submucosal Dissection for Colorectal Laterally Spreading Lesions.
|
N/A | |
Completed |
NCT00478634 -
A Phase 1 Study Investigating the Combination of RAD001, Cetuximab and Irinotecan as Second-line Therapy After FOLFOX (or XELOX) Plus Bevacizumab in Patients With Metastatic Colorectal Cancer
|
Phase 1 | |
Active, not recruiting |
NCT03885817 -
Physically Active During Cancer Treatment (FAKT)
|
N/A | |
Completed |
NCT01139138 -
Safety Study of the Combination of Panitumumab, Irinotecan and Everolimus in the Treatment of Advanced Colorectal Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT06118125 -
Delay to Diagnosis in Digestive Cancerology by the General Practitioner Related to Covid-19 Pandemic Confinement
|
||
Completed |
NCT00540943 -
Study of Pazopanib, Irinotecan and Cetuximab in Combination to Treat 2nd Line Metastatic Colorectal Cancer
|
Phase 1 | |
Not yet recruiting |
NCT01157052 -
Oxaliplatin Pharmacokinetics With and Without Ca2+/MG2+ Infusion in Colorectal Cancer Patients
|
Phase 1 | |
Completed |
NCT01671592 -
Safety of Labeled Dendritic Cell (DC) Vaccines and Feasibility of Tracking by Magnetic Resonance Imaging (MRI)
|
Phase 1 | |
Completed |
NCT00920803 -
A Clinical Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of SRT501 in Subjects With Colorectal Cancer and Hepatic Metastases
|
Phase 1 |